Tag: tirzepatide
Lilly and Cipla sign a distribution & promotion agreement for type...
Under this agreement, Cipla will market tirzepatide under the brand name Yurpeak
Eli Lilly’s Tirzepatide approved by NMPA in China, boosting market position
Tirzepatide’s debut as the first dual GIP and GLP-1 receptor agonist for obesity in China strengthens Eli Lilly’s presence
Viking Therapeutics’ obesity drug VK2735 could rival Eli Lilly’s Tirzepatide, says...
New Phase IIa results reveal significant weight loss, positioning VK2735 as a potential market leader amid increasing competition